Sonnet Bio Therapeutics Files to Sell 5.77M Shares of Common Stock for Holders
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersDermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares r
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results.Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, be
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersMolecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) s
Express News | Sonnet BioTherapeutics Shares Are Trading Lower After the Company Announced the Exercise of Warrants for Gross Proceeds of $3.4 Million
Express News | Sonnet BioTherapeutics Announces Exercise Of Warrants For Gross Proceeds Of $3.4M
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today
Express News | Sonnet Biotherapeutics - Il-18 Clinical Trials Have Shown That, Although It Is Well Tolerated, Il-18 Has Poor Efficacy in Treatment of Cancers
Express News | Sonnet Biotherapeutics- Il-18(Bpr) Was Linked to Sonnet's Proprietary Tumor Targeting F(H)AB Platform, With or Without Single-Chain Wild-Type Il-12
Express News | Sonnet Biotherapeutics Holdings Inc - Il-18(Bpr) and Il-12 Could Be Combined for Broad Applications in Oncology and Cell-Based Therapies
Express News | Sonnet Biotherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, Son-1411 and Son-1400, Each Containing a Variant Il-18 Domain
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $30 Price Target
Express News | Sonnet Biotherapeutics - Board Initiated Process to Explore and Review a Range of Strategic Alternatives Focused on Maximizing Stockholder Value
Express News | Sonnet Biotherapeutics Holdings Inc - Announces Review of Strategic Alternatives
Express News | Sonnet Biotherapeutics: Clinical Benefit Seen at 4 Months Post-Initiation of Dosing in 35% of Evaluable Patients (8/23) With Advanced Solid Tumors
Express News | Sonnet Biotherapeutics: Announces Updated Clinical Data for Son-1010 as Monotherapy/Combined With Anti-Pd-L1, With Increase in Dose-Escalation Target
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined With an Anti-PD-L1, Along With an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
No Data